Q32 Bio (QTTB) investor relations material

Strategic focus and therapeutic innovation

• Advancing immune therapeutics with a lead focus on alopecia areata (AA) using bempikibart, an IL-7Ra antagonist antibody with dual IL-7/TSLP inhibition and a differentiated safety profile compared to JAK inhibitors.

• Bempikibart demonstrated proof of concept in AA, showing robust biomarker changes, durable hair regrowth, and a favorable safety profile in clinical trials.

• The company’s pipeline includes wholly-owned programs targeting severe inflammatory and autoimmune diseases, with ongoing evaluation of complement inhibitor assets.

Clinical development and trial results

• SIGNAL-AA Phase 2a Part A showed durable and sustained hair regrowth, with continued improvement post-treatment and no Grade 3 or higher related adverse events.

• Part B is fully enrolled, with 36-week topline results expected mid-2026; loading regimen achieves steady-state drug concentration 9 weeks earlier than Part A.

• Durable responses observed in both severe and very severe AA patients, including those with long-standing disease, supporting potential for remittive effect.

• Bempikibart’s mechanism targets pathogenic T-cells and restores immune tolerance, addressing the root cause of hair follicle destruction.

Market opportunity and competitive positioning

• AA affects 700,000 people in the U.S., with a projected $2.6B market by 2030; current therapies lack desired safety and durability.

• JAK inhibitors, while effective, carry black box warnings and require chronic use; bempikibart offers a potentially safer, durable alternative.

• KOL feedback highlights the value of a product with remittive properties and minimal safety concerns, positioning bempikibart as a potential first-line therapy.